jcm-logo

Journal Browser

Journal Browser

Clinical Diagnosis and Treatment of Uveitis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".

Deadline for manuscript submissions: 20 September 2026 | Viewed by 761

Special Issue Editor


E-Mail Website
Guest Editor
Department of Ophthalmology, University Hospital Center Zagreb, School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia
Interests: uveitis; intraocular tumors; medical retina; pediatric retina
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The term uveitis encompasses a large number of heterogeneous diagnoses of intraocular inflammation of various causes. The immune specificities of the intraocular compartment, immune dysregulation, genetic background, infections and other environmental factors, and especially the necessary joint action of predisposing factors for the development of the disease, form a fascinating pathophysiological line that is a great challenge for clinicians but also for experts engaged in basic research. Due to its pathophysiological heterogeneity, dealing with uveitis requires both basic medical knowledge and the application of new knowledge and biotechnologies that are applicable to this issue. We have witnessed great progress in the discovery of pathophysiology, diagnostics, and treatment in medicine in recent decades, which is also visible in the approach to uveitis. Therefore, this area of clinical ophthalmology represents a great challenge and offers broad opportunities for research work. All authors involved in basic and clinical research in uveitis are welcome in this Special Issue.

Dr. Nenad Vukojević
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • uveitis
  • intraocular tumors
  • medical retina
  • pediatric retina

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

24 pages, 2608 KB  
Article
Systemic Immunomodulatory Therapy, Anterior Chamber Inflammation, and the Use of Topical Corticosteroids in Juvenile Idiopathic Arthritis-Associated Uveitis: A Long-Term Real-Life Observational Study
by Marija Barišić Kutija, Sanja Perić, Mario Šestan, Petra Kristina Ivkić, Martina Galiot Delić, Tomislav Jukić, Josip Knežević, Marijan Frković, Vladimir Trkulja, Marija Jelušić and Nenad Vukojević
J. Clin. Med. 2026, 15(2), 812; https://doi.org/10.3390/jcm15020812 - 19 Jan 2026
Viewed by 458
Abstract
Background: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is a rare condition, and assessment of the efficacy of disease-modifying antirheumatic drugs, synthetic (sDMARD) or biological (bDMARD), in randomized trials is hindered by this fact. Methods: In this prospective longitudinal study, we observed 38 children aged [...] Read more.
Background: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is a rare condition, and assessment of the efficacy of disease-modifying antirheumatic drugs, synthetic (sDMARD) or biological (bDMARD), in randomized trials is hindered by this fact. Methods: In this prospective longitudinal study, we observed 38 children aged 1.3 to 15.2 years, with 69 eyes affected with JIA-U for 1970 overall eye examinations (6–59, median 16) irregularly scattered across 4.4–87.6 months (median 21.6) of follow-up, with on- and off-periods of DMARD use and use of topical treatments. Results: With adjustment for several time-invariant and time-varying covariates, periods of exposure to sDMARD vs. no DMARD exposure were associated with peak benefits of 15–20% lower probability of having more severe anterior chamber (AC) inflammation and a similar relative reduction in the daily use of topical corticosteroids (TCS). Periods of bDMARD exposure or of bDMARD + sDMARD exposure vs. no DMARD use were associated with peak benefits of an around 50% reduction in the probability of having more severe AC inflammation, and peak benefits of an around 60–65% reduction in TCS use. Conclusions: The observations regarding bDMARD (only) or bDMARD + sDMARD exposure are in agreement with the extent of benefits suggested for adalimumab vs. placebo (+background sDMARD) in the only existing randomized trial in this setting evaluating AC inflammation and TCS use. Full article
(This article belongs to the Special Issue Clinical Diagnosis and Treatment of Uveitis)
Show Figures

Figure 1

Back to TopTop